- So my name is Andrea Buono. I am an interventional cardiologist working at Fondazione Poliambulanza in Brescia in Italy. And today I will discuss the results of the ITAL-neo registry, a study assessing the safety and efficacy of the new generation ACURATE neo2 transcatheter aortic valve in the context of TAVI.
Background of This Study
Background of the ITAL-neo registry has to be searched on the available evidence produced so far in literature demonstrating the non-negligible incidence of more than mild paravalvular leak with the use of the early generation ACURATE neo in the context of TAVI. For this reason, the producing company, the Boston scientific, has launched on the market at the end of September, 2020 the new iteration, called ACURATE neo2.
Study Design and Patient Population
The device used in the study is the ACURATE neo2. This valve maintain the key feature of the previous generation valve, but incorporates some engineering refinement such as the presence of a radio pack marker on the delivery system, able to guarantee a more precise implantation, but also the presence of a total outer pericardial skirts which reach the upper crown and with an active technology able to guarantee a more synchronous adaptation to the native annulus, with the potential to reduce the incidence of moderate or greater paravalvular leak.
Study Design and Patient Population
Our study is a retrospective, observational, multi-center, independent registry. We enrolled 900 patients consecutive, affected by severe aortic valve stenosis treated in 13 Italian centers which received both generation device. Of the 900 patients, 680 received the earlier generation device, whereas 220 were treated with the ACURATE neo2 valve. To account for the non-randomized nature of the study, we perform the 1:1 propensity score match in order to have the final results of 205 pairs of patients.
Key Findings
The primary endpoint is the incidence of moderate or greater paravalvular leaks at pre-discharge echocardiographic assessment. Whereas secondary endpoints are technical success, but also some short-term clinical outcome intended as 90 days safety, 90 days efficacy, and a single component of the pre-specified composite endpoint. All the endpoints were assessed according to the model BARC three criteria. We demonstrate a significant reduction of the primary endpoint with the use of new generation ACURATE neo2 that occurred in 3.5% of the patients, compare with 11.2% of patients treated with the early generation device. Also the technical success were high in both groups with comparable results. And this is intuitive since this definition does not include the presence of more moderate or greater paravalvular leaks, but also data concerning the short-term clinical outcome are encouraging because we see a higher number of safety and efficacy 90-day success with new generation device.
Take-Home Messages
My take-home message is that ACURATE neo2 is improve its performance especially in the context to reduce paravalvular leak. And I think now this valve is ready to be used in a broad and large population of patients, in the context of TAVI.
Further Study Required
We need randomised controlled trial to confirm our preliminary results.
EuroPCR 2022: Late-breaking Science Video Collection
Published: 13 May 2022
-
Views:
2479
-
Likes:
7
-
Views:
2479
-
Likes:
7
-
Up Next
-
4m 20s
-
2m 18sPart 2 | Session 9 EuroPCR 22: SYNERGY™ Non-inferior to BioMatrix NeoFlex in OCT SORT-OUT VIII
-
5m 9s
-
7m 18sPart 2 | Session 11 EuroPCR 22: Balloon Vs Self-Expanding Valves in Valve-in-Valve TAVI
-
5m 52sPart 2 | Session 12 EuroPCR 22: MitraClip in Atrial Functional Mitral Regurgitation
-
2m 15sPart 2 | Session 13 EuroPCR 22: SCB with Micro-Reservoir Technology in Coronary Lesions
-
4m 46sPart 2 | Session 14 EuroPCR 22: FORWARD PRO Study Shows No Durability Issues After 3 Years
-
4m 25sPart 2 | Session 15 EuroPCR 22: DEB & DES in the Treatment of Diffuse CAD
-
3m 16sPart 2 | Session 16 EuroPCR 22: EASTBOURNE Registry indicates Satefy of Sirolimus-Coated Balloon
-
4m 27sPart 2 | Session 17 EuroPCR 22: JenaValve TAVR System for the Treatment of Aortic Regurgitation
-
7m 7sPart 2 | Session 18 EuroPCR 22: Transcatheter Tricuspid Valve Repair with PASCAL System
-
6m 53s
-
20m 24sPart 1 | Session 1 EuroPCR 22 Late-breaking Science Preview Joost Daemen, Nicolas M Van Mieghem
-
27m 14sPart 1 | Session 2 EuroPCR 22 Late-breaking Science Wrap-Up Nicolas M Van Mieghem, Joost Daemen
-
3m 28sPart 2 | Session 1 EuroPCR 22: AQVA Study Shows Superiority in QFR-Based Virtual PCI Arm Simone Biscaglia
-
5m 10sPart 2 | Session 2 EuroPCR 22: Patient-Level Pooled Analysis of Ultrasound RDN in radiance-HTN SOLO & Trio Ajay J Kirtane
-
7m 50sPart 2 | Session 3 EuroPCR 22: Optimize PRO Interim Analysis Finds New Technique is "Best-in-Class" Kendra J Grubb
-
5m 56sPart 2 | Session 4 EuroPCR 22: MASTER-DAPT Sub-Analysis Shows Consistent Results in Complex PCI Patients Marco Valgimigli
-
3m 34sPart 2 | Session 5 EuroPCR 22: CRUZ-HBR Indicates Use Of Supraflux™ Cruz Stent Is Favourable David Leistner
-
4m 49sPart 2 | Session 6 EuroPCR 22: ASTRO-TAVI Shows Improved Neurological Outcomes With Neurointervention Amos Levi
Overview
Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science trials and spotlight questions that could change treatment strategies in interventional cardiology.
Short, accessible Expert Interviews will be available with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
Part 1
View from the Thoraxcenter
In this concise episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their take on the most anticipated late-breaking science form EuroPCR 2022.
Part 2
Expert Interviews
Short, accessible Expert Interviews with select faculty focusing on the results, applicability, and impact on future research.
Faculty Biographies
Transcript